Quality of life and COPD;Calidad de vida y EPOC

Revista Clinica Espanola

Volumn 209, Issue 2, 2009, Pages 59-60

  Escudero, J C Martín ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ASPIRATION; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; EDITORIAL; EVALUATION; FORCED EXPIRATORY VOLUME; HEALTH CARE QUALITY; MEDICAL RESEARCH; MOBILIZATION; MORTALITY; OXYGEN THERAPY; PERCEPTION; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE;

HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 65549121317     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/S0014-2565(09)70626-5     Document Type: Editorial

References (11)

1. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. En: GOLD-Global initiative for chronic obstructive lung disease; 2003.p1-30.
2. Medidas específicas de la calidad de vida relacionadas con la salud X. Badia M. Salamero J. Alonso La medida de la salud. Guía de escalas de medición en español 2 ed. 1999 Ed. Edimac Barcelona 175 190
3. Y. Oba Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease Mayo Clin Proc 82 2007 575 582 (Pubitemid 46709427)
4. J.D. Miller , R.A. Malthaner , C.H. Goldsmith , R. Goeree , D. Higgins , P.G. Cox For the Canadian Lung Volume Reduction Surgery Study A randomized clinical trial of lung volume reduction surgery versus best medical care for patients with advanced emphysema: a two-year study from Canada Ann Thorac Surg 81 2006 314 321 (Pubitemid 41815426)
5. M.P. Rutten-van Mölken , J.B. Oostenbrink , M. Miravitlles , and B.U. Monz Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain Eur J Health Econ 8 2007 123 135 (Pubitemid 46742896)
6. A.H. Briggs , and G. Lozano-Ortega Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data Value in Health 9 2006 227 235 (Pubitemid 44126777)
7. S.F. Hurley , and J.P. Matthews The quit benefits model: a markov model for assessing the health benefits and health care cost savings of quitting smoking Cost Eff Resour Alloc 5 2007 2 (Pubitemid 46306378)
8. B.R. Celli , C.G. Cote , J.M. Marin , C. Casanova , M. Montes de Oca , and R.A. Méndez The body-mass index, airflow obstruction, dyspnea, and exercice capacity index in chronic obstructive pulmonary disease N Engl J Med 350 2004 1005 1012 (Pubitemid 38269277)
9. S. Spencer , P.M. Calverley , P. Sherwood Burge , and P.W. Jones Health status deterioration in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 122 128 (Pubitemid 32095261)
10. M. Miravitlles , M. Ferrer , A. Pont , R. Zalacain , J.L. Álvarez Sala , and F. Masa Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study Thorax 59 2004 387 395 (Pubitemid 38624744)
11. P. Almagro , E. Calbo , A. Ochoa de Echaguen , B. Barreiro , S. Quintana , and J.L. Heredia Mortality after hospitalization for COPD Chest 121 2002 1441 1448 (Pubitemid 34499653)